Intense Treatment Regimen With Intravitreal Aflibercept Injection

Inclusion Criteria: * Age ≥ 50 years * Choroidal neovascularization related to age-related macular degeneration * Prior treatment with any anti-VEGF agent for ≥ 12 months * Prior treatment with at least five consecutive IAI at baseline with an average treatment interval of maximum 35 days * Presence of foveal fluid at most recent clinical visit occurring 30 (+/- 5) days following the most recent IAI * Willing and able to comply with clinic visits and study-related procedures * Provide signed informed consent Exclusion Criteria: A patient who meets any of the following criteria will be excluded from the study: * Monocular patients * Patients with a previous history of macular thermal laser or PDT * Confounding ocular conditions in the study eye that may affect interpretation of OCT, BCVA or assessment of macular appearance (eg. cataract, epiretinal membrane, retinal vascular occlusive disease) * Intraocular surgery (including cataract surgery) in the study eye within 2 months preceding baseline * History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD in the study eye * Active intraocular inflammation (grade trace or above) in the study eye * History of rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in the study eye * Uncontrolled glaucoma in the study eye (defined as IOP ≥ 30 mmHg despite treatment with anti-glaucoma medication) * History of cerebral vascular accident, myocardial infarction, transient ischemic attacks wi…